


- the VISTA and VIVID studies. *Ophthalmology*. 2015;122:2044–2052.
37. Ford I, Norrie J. Pragmatic trials. *N Engl J Med*. 2016;375(5):454–463.
 38. Loudon K, Treweek S, Sullivan F, et al. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ*. 2015;350:h2147.
 39. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med*. 2015;372(13):1193–1203.
 40. Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. *Lancet*. 2022;399(10326):741–755.
 41. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2011;364(20):1897–1908.
 42. Mosely JEMA. Visual function endpoints: the regulatory perspective. European Medicines Agency. Available at: https://www.ema.europa.eu/documents/presentation/presentation-day-1-visual-function-endpoints-regulatory-perspective_en.pdf; 2011. Accessed October 14, 2022.
 43. Luttrull JK, Sinclair SH. Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity. *Retina*. 2014;34(10):2010–2020.
 44. Vujosevic S, Martini F, Longhin E, et al. Subthreshold micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema: morphologic and functional safety. *Retina*. 2015;35(8):1594–1603.
 45. Wells-Gray EM, Doble N, Ohr MP, Choi SS. Structural integrity of individual cone photoreceptors after short-wavelength subthreshold micropulse laser therapy for diabetic macular edema. *Ophthalmic Surg Lasers Imaging Retina*. 2018;49(12):946–954.
 46. Gallagher MJ. Introduction of a nurse-led intravitreal injection service in ophthalmology. *Br J Nurs*. 2017;26(14):800–803.
 47. Flood D, Seiglie JA, Dunn M, et al. The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults. *Lancet Healthy Longev*. 2021;2:e340–e351.
 48. Seiglie JA, Marcus ME, Ebert C, et al. Diabetes prevalence and its relationship with education, wealth, and BMI in 29 low- and middle-income countries. *Diabetes Care*. 2020;43:767–775.
 49. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Res Clin Pract*. 2017;128:40–50.

Pictures & Perspectives



Rapid Involution of Presumed Pyogenic Granuloma with Topical Timolol

Four months before presentation, a 27-year-old man had eyelid laceration repair after trauma to his right eyelids. He went to the emergency department (ED) with an enlarging and increasingly painful eyelid mass in addition to purulent discharge. He initially noticed the mass after surgery and experienced pain and subjectively blurry vision after surgery. He confirmed that the mass would bleed on occasion. Upon evaluation in the ED, visual acuity was 20/25 at near vision, and the mass was in contact with the cornea, 1 cm in size, firm, mobile, and attached firmly by a stalk to the palpebral conjunctiva (Fig A, lid everted). With a presumed diagnosis of a pyogenic granuloma, the patient was prescribed timolol twice daily and trimethoprim/polymyxin 4 times daily, and at follow-up 2 days later, the mass and his symptoms had resolved; visual acuity was 20/20 at distance (Fig B, lid everted) (Magnified version of Fig A-B is available online at www.aojournal.org).

AARON PRILUCK, MD

COLIN BACORN, MD

FATEMEH RAJAIL, MD, PhD

Wilmer Eye Institute, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland